Meta-analysisindependent cross-checkabstract only checked I-ODD-11 standard review
GLP-1 drugs and pancreatitis in trials
Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes.
Overview
Storgaard H et al.. Diabetes Obes Metab 2017 · PMID 28105738 · DOI 10.1111/dom.12885
In large blinded trials, pancreatitis was not more frequent with GLP-1 drugs than placebo.
Does the study support the specific claim? No · Methodological quality: high
Plain-language summary
Study explained simply
- What did the researchers want to find out?
GLP-1 RAs and acute pancreatitis
- How was the study done?
Systematic review and meta-analysis of long-term placebo-controlled RCTs with adjudicated pancreatitis
- How many people, animals or samples were studied?
3 RCTs; 9,347 vs 9,353; Type 2 diabetes
- What was actually found?
OR 0.745 (n.s.).
- How large was the observed effect?
Peto OR 0.745 (0.47-1.17)
- What do the results mean in everyday life?
No clear pancreatitis risk.
- What are the study's limitations?
Only 3 trials; Rare outcome
- What does it say about Elawady's specific claim?
Contradicts C-ODD-04.
- Do the results apply to Germany and Europe?
Multinational trial including European sites or directly applicable to EU practice.
- What can explicitly not be concluded from this study?
Exclude very small risk.
Scientific in-depth review
1. Full reference
- Authors
- Storgaard H et al.
- Journal
- Diabetes Obes Metab
- Year
- 2017
- Identifier
- PMID 28105738 DOI 10.1111/dom.12885
- Verification
- verified – PubMed efetch 2026-10-25 (this agent)
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
not stated in abstract
2. Research question
GLP-1 RAs and acute pancreatitis
3. Study design and population
- Study design
- Meta-analysis – Systematic review and meta-analysis of long-term placebo-controlled RCTs with adjudicated pancreatitis
- Population
Type 2 diabetes
- Country
International
- Period
RCTs >=24 months
- Sample size
3 RCTs; 9,347 vs 9,353
- Inclusion and exclusion criteria
As described in the abstract; details not available in abstract.
4. Methods and endpoints
- Exposure / intervention
GLP-1 RAs
- Comparator
Placebo
- Endpoints
Acute pancreatitis
- Statistical methods
Peto OR; trial sequential analysis
5. Actual results
- Results
Peto OR 0.745 (0.47-1.17); TSA suggested more evidence needed.
- Absolute risks
not reported
- Authors' conclusion
No evidence that GLP-1 RA treatment increases acute pancreatitis.
6. Strengths
- Blinded adjudication
7. Weaknesses
- Only 3 trials
- Rare outcome
8. Risk of bias
- Orienting tool
- AMSTAR 2
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- low
- Rationale
High-quality RCT inputs.
9. Assessment of the statistical interpretation
CI does not exclude small increase.
10. Relevance to the specific claim
Contradicts C-ODD-04.
11. Independent contrary findings
12. Transferability to Germany and Europe
Multinational trial including European sites or directly applicable to EU practice.
13. Overall methodological judgement
Best evidence on pancreatitis: no increase shown.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | high |
| Risk of bias | low |
| Precision of results | low |
| Directness | direct |
| Reproducibility | partly replicated |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
None beyond those stated.
15. Linked fact checks
- Injectable diabetes and weight-loss drugs (GLP-1 receptor agonists) can trigger pancreatitis and cysts. – Studies contradicting or limiting the claim